Telmisartan and obesity

Internal Medicine

Volumn 49, Issue 19, 2010, Pages 2191-

  Fernández Fernández, Francisco José ^a  

^a Universidad de La Coruña   (Spain)

Author keywords

Obesity; PPAR ; Telmisartan

Indexed keywords

CANDESARTAN; FATTY ACID; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RISPERIDONE; TELMISARTAN;

ADIPOGENESIS; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATTY ACID METABOLISM; HUMAN; INTRAABDOMINAL FAT; LETTER; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROADIPOCYTE; PROTEIN EXPRESSION; SCHIZOPHRENIA; WEIGHT GAIN;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; HUMANS; OBESITY; PPAR DELTA; RISPERIDONE; SCHIZOPHRENIA; WEIGHT LOSS;

EID: 77958095434     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3956     Document Type: Letter

References (3)

1. Yamaguchi K, Tsutsumi E. The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. Intern Med 49: 919-923, 2010.
2. He H, Yang D, Ma L, et al. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-d-dependent pathways. Hypertension 55: 869-879, 2010.
3. Barish GD, Narkar VA, Evans RM. PPARδ: a dagger in the heart of the metabolic syndrome. J Clin Invest 116: 590-597, 2006.